Background: Chordoid Meningioma is a rare brain tumour characterized genetically by loss of genetic material from chromosome 22q at cytogenetic level resulting in mutation of NF2 gene. Objectives and case report: In the present report, we described a rare case of suprasellar chordoid meningioma, which presented in a 32-year-old-woman. Her only complain was throbbing headache. Neurological examination showed left temporal hemianopia, decreased visual acuity (3/6), and no physical abnormalities related to Castleman syndrome were noted. Cranial magnetic resonance (MR) images demonstrated a 28x15 mm mass in the sellar region, which showed iso-to low intensity that enhanced vividly after gadolinium with upwards displacement of the Optic chiasm. Total surgical excision of the tumour was performed and subsequent histological examination of the tumour showed typical histology pattern of chordoid meningioma grade II according to the WHO classification system of meningiomas. Genomic DNA was extracted and mutation analysis for INI1 gene using primer of exon 4, 5, 7, and 9 showed mutation involving exon 9. DNA sequencing showed heterozygosity C-T mutation in exon 9 of INI1 gene leading to change of amino acid serine to phenylalanine at (codon 63). The details of this case are presented with a review of the literature.
Introduction
Chordoid meningioma, accounts for 0.5% of all intracranial meningiomas. It was first described by Kepes et al., in 1988 , and accepted as meningiomas variants by the WHO classification of the central nervous system tumour in 19931,2.
Association of the tumour with haematologic abnormality such as microcytic anaemia and dysgammaglobulinemia and/or Castleman syndrome have been repeatedly reported, especially, in paediatric patients [1] , although chordoid meningioma with no hematological abnormalities have also been reported [3, 4] .
Microscopically chordoid meningiomas have features of meningioma similar to chordoma which is usually characterized by epitheliod cord like tumour cells. It is classified as WHO grade II tumour [5] . There are eosinophilic vacuolated cells within a myxoid stroma and a lymphoplasmocytic infiltrate is often apparent and might be associated with haematological abnormalities [6] .
Cytogenetic analysis revealed that monosomy 22 is a common, early, and perhaps primary event in the genesis of meningioma. Molecular analysis has identified several important candidate genes. Of those, Neurofibromatosis 2 (NF2), Tumour Suppressor in Lung Cancer-1 (TSLC1), and TP53 are the most commonly reported.
The INI1 (SMARCB1/hSNF5) gene, maps to chromosome 22q11.2, is part of the SWI/SNF complex participating in transcriptional regulation by remodeling chromatin in an ATP-dependent manner [7] . The SWI/SNF complex seems to be involved in DNA replication [8] . These features characterize members of the SWI/SNF complex as interesting targets for genes which may be involved in tumour formation.
Recently, INI1 has been shown to carry mutations predominately in some central nervous system tumours such as meningiomas [9] , schwannomas [10] , astrocytomas11, ependymomas12 and glioblastomas11). INI1, therefore, is an interesting candidate gene for brain tumours, especially those entities that exhibit allelic loss on chromosome 22.
Material and Methods

The Case
A 32-year-old-female lady presented with four months history of throbbing headache and left visual field and acuity defect that worsened over the last three weeks. Neurological examination showed left temporal hemianopia, decreased visual acuity (3/6), and no physical abnormalities related to Castleman disease. Part of the tumour was fixed in 10% neutral formalin for histopathology examination.
The other part was kept for molecular studies.
Molecular Analysis
Genomic DNA was isolated using chloroform phenol extraction methods. PCR was performed under standard conditions using dNTPs, Taq DNA polymerase (Promega, Madison, Wisconsin, USA), and a Biometra UNO Thermoblock (Biometra, Gottingen, Germany).
Primers of exon 4, 5, 7, and 9 for INI1 gene, were analyzed by SSCP and direct sequencing employing a set of primers specified PCR products on acrylamide gel using SSCP analysis was performed on apparatus using 12% acrylamide gels. Electrophoresis was run at 2-6 W and variable temperatures. 
Sequencing
The same primers used for PCR analysis were used for sequencing. PCR products samples were sent for commercial sequencing at Macrogen, Seoul, Republic of Korea.
The BLAST (Basic Local Alignment Search Tool) programmer at the site of National
Center for biotechnology Information (NCBI) was used for individual alignment of our samples.
Results
Following surgery the patient had an uneventful postoperative recovery; the headache subsided and the visual acuity markedly improved to 5\6. Postoperative values of T3, T4, TSH and prolactin were within normal ranges.
Microscopic examination of the tumour specimen revealed cluster of cohesive cells with dark regular nuclei and tapering cytoplasm arranged in a fibrous stroma showing an intense lymphocytic and plasma cells infiltration. There were scattered Russell bodies in the inflammatory reaction (Figure 2 ). The diagnosis of chordoid meningioma with inflammatory reaction WHO Grade II was made and hence the patient was submitted to conformal radiotherapy [14, 15] . The postoperative MRI revealed total removal of the tumour (Figure F1-B) .
Molecular results
The sequencing indicated that the mutation was heterozygotic with heterozygosity C-T mutation in exon 9 of INI1 gene, the mutation changed in the amino acid serine to phenylalanine in (codon 63) in this polymorphism data not reported in data analysis programmer. been reported [18, 19] . The present case did not show features of Castleman syndrome.
Discussion
Chordoid meningioma is a rare variant of meningioma; the differential diagnosis includes glioma, myxoid chondrosarcoma, chondroid chordoma, and other variants of meningiomas [4, [19] [20] [21] . Usually they show trabeculae or cords of eosinophilic vacuolated cells in myxoid matrix [22] . 
